Hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide and method for preparing same
US9950071B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2015 |
| Grant date | Apr 24, 2018 |
| Priority date | — |
| Expiry date | Jan 5, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23V2002/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide. The hybrid anticancer prodrug according to the present invention sequentially releases quinone methide and cinnamaldehyde by H2O2 and acidic pH, and thus alkylates antioxidant GSH through the release of quinone methide, thereby inhibiting an antioxidative system and increasing oxidation stress, and generates and accumulates reactive oxygen species (ROS) through the release of cinnamaldehyde, thereby promoting apoptosis, and thus the hybrid anticancer prodrug according to the present invention can be favorably used as an anticancer drug by creating a synergetic anticancer effect through double stimulus-response and sequential treatment action in a cancer cell-specific manner.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.